The senescence-inhibitory p53 isoform Δ133p53α represses the proinflammatory chemokine CXCL10 in progeria model mice and naturally aged mice

This study demonstrates that the senescence-inhibitory p53 isoform Δ133p53 extends lifespan and counteracts aging in progeria and naturally aged mice by repressing the proinflammatory chemokine CXCL10, a finding supported by inverse associations observed in human tissue datasets.

The Gist

Imagine your body is a bustling city. As the city ages, the streets get clogged with trash, the buildings start to crumble, and the air becomes filled with smoke. In biological terms, this "trash" and "smoke" are inflammation and cellular senescence (when cells stop dividing but don't die, instead becoming toxic).

This paper is about a specific "superhero" protein inside our cells called p53. Usually, p53 is a good guy that stops cancer, but it has a dark side: when it gets too active in old age, it forces cells to stop working and start spewing out toxic smoke, speeding up aging.

However, nature has a backup plan. There is a special version of this protein, called Δ133p53α (let's call it "Delta" for short). Delta is like a peacekeeper or a fire extinguisher. It doesn't stop the bad guys (cancer) from being caught, but it stops the "good" p53 from overreacting and causing unnecessary chaos (aging).

Here is the story of what the scientists discovered, broken down into simple parts:

1. The Problem: The "Progeria" City

The researchers used a special type of mouse that ages incredibly fast, like a human living 70 years in just a few months. This is called a progeria model.

• The Issue: These mice are full of toxic smoke. Their bodies are flooded with inflammatory chemicals (cytokines) that make them sick and old very quickly.
• The Known Fix: The scientists already knew that if they added the "peacekeeper" protein (Delta) to these mice, the mice lived longer and looked healthier. They knew Delta lowered one specific type of smoke called IL-6.

2. The Detective Work: Finding the Other Smoke

The scientists asked, "Is IL-6 the only toxic smoke, or are there others?"
They took a "chemical census" (a Luminex assay) of the blood from these mice. Think of this like a police scanner listening to all the emergency calls in the city.

• The Discovery: They found that Delta didn't just lower IL-6. It also lowered three other toxic chemicals: CXCL1, IL-1α, and a new suspect they hadn't looked at before: CXCL10.

3. The New Suspect: CXCL10

CXCL10 is like a siren that calls in the immune system's "heavy artillery" (white blood cells). In a healthy young city, this siren is useful for fighting infections. But in an old, stressed city, the siren is blaring 24/7, causing panic, inflammation, and damage to organs like the liver, brain, and spleen.

• The Finding: The study showed that in the fast-aging mice, the CXCL10 siren was screaming loudly. But when the "peacekeeper" (Delta) was present, the siren was silenced.
• The Proof: They checked the organs (liver, brain, spleen) and found that the instructions to make this siren (the genes) were turned down whenever Delta was active.

4. Does This Happen in "Normal" Aging?

The scientists wondered, "Does this only happen in these fast-aging mice, or does it happen to us too?"
They tested normal, old mice (2 years old, which is like a human in their 70s).

• The Result: Even in normal mice, as they got old, the CXCL10 siren started blaring. But, if the mice had the "peacekeeper" (Delta), the siren was kept quiet.
• The Human Connection: They looked at data from human tissue samples (the GTEx database). They found that in human spleens, when the "peacekeeper" (Delta) was high, the "siren" (CXCL10) was low. It's an inverse relationship, just like in the mice.

5. The "Direct" Connection

To make sure Delta was actually telling the cell to stop making the siren (and not just doing it by accident over time), they did a quick experiment in a petri dish.

• They turned on Delta for just 5 days.
• Boom: The CXCL10 levels dropped immediately. This proves Delta is the direct boss that shuts off the siren.

The Big Picture: Why This Matters

Think of aging as a city where the fire alarms are stuck in the "ON" position, causing panic and damage.

• Old View: We knew one alarm (IL-6) was the main problem.
• New View: This paper says, "Hey, there's another alarm (CXCL10) that's just as loud and damaging, and our internal peacekeeper (Delta) knows how to shut it off."

Why is this exciting?
If we can find a way to boost this "peacekeeper" protein (Delta) in humans, or if we can use drugs to silence the "CXCL10 siren" directly, we might be able to:

1. Slow down the aging process.
2. Treat diseases caused by inflammation (like liver disease or Alzheimer's).
3. Help people with progeria (and eventually, normal aging) live longer, healthier lives with less pain and inflammation.

In short: Delta is the quiet hero that turns down the volume on the body's inflammatory noise, and CXCL10 is one of the loudest noises it silences.

Technical Summary

Title

The senescence-inhibitory p53 isoform Δ133p53α represses the proinflammatory chemokine CXCL10 in progeria model mice and naturally aged mice.

1. Problem Statement

• Context: Cellular senescence and the associated secretory phenotype (SASP) drive aging and age-related diseases. The p53 protein is a key regulator of senescence, but it also has isoforms with distinct functions.
• Specific Gap: While the full-length p53 promotes senescence, the N-terminally truncated isoform Δ133p53α acts as a dominant-negative inhibitor of p53-mediated senescence. Previous work showed that expressing Δ133p53α in progeria model mice (Lmna^G609G/+^) extends lifespan and reduces systemic inflammation, specifically by lowering IL-6 levels.
• Unresolved Question: The broader inflammatory profile regulated by Δ133p53α remains unclear. Specifically, it is unknown which other cytokines or chemokines are modulated by this isoform and whether these changes contribute to its anti-aging effects in both accelerated (progeria) and natural aging contexts.

2. Methodology

The study employed a multi-faceted approach combining in vivo mouse models, in vitro cell culture, and human bioinformatics:

• Animal Models:
  • Progeria Model: Heterozygous Lmna^G609G/+^ mice (mimicking Hutchinson-Gilford Progeria Syndrome).
  • Transgenic Expression: Inducible expression of human Δ133p53α via Cre-ERT2/tamoxifen system.
  • Groups: Included Δ133p53α-expressing mice, non-expressing controls (with/without tamoxifen), and wild-type (WT) controls.
  • Aging Models: 15-week-old (young), 10-month-old (middle-aged), and 2-year-old (naturally aged) mice.
• Serum Profiling:
  • Luminex Multiplex Assay: A 32-plex quantitative assay was performed on serum samples from 15-week-old progeria mice to screen for changes in cytokines and chemokines.
• Tissue Analysis:
  • qRT-PCR: Quantitative real-time PCR was used to measure Cxcl10 mRNA levels in the spleen, brain, liver, and lung.
• In Vitro Validation:
  • Mouse Embryonic Fibroblasts (MEFs): Engineered to express progerin (to induce senescence) and inducible Δ133p53α.
  • Human Fibroblasts: Derived from Hutchinson-Gilford Progeria Syndrome (HGPS) patients, transduced with lentiviral Δ133p53α.
  • Protocol: Short-term (5-day) induction of Δ133p53α to assess direct regulatory effects.
• Human Data Analysis:
  • GTEx Dataset: Analysis of postmortem RNA-seq data (v8) to correlate endogenous Δ133p53α and CXCL10 expression levels across human tissues.

3. Key Contributions

• Discovery of CXCL10 as a Novel Target: Identified CXCL10 (IP-10) as a specific proinflammatory chemokine repressed by Δ133p53α, expanding the known anti-inflammatory targets beyond IL-6.
• Differentiation of Aging Models: Demonstrated that Δ133p53α-mediated repression of CXCL10 occurs in both accelerated aging (progeria mice) and natural aging (2-year-old WT mice).
• Mechanistic Insight: Provided evidence that the repression is likely a direct transcriptional regulation rather than a long-term adaptive response, based on rapid in vitro reversal of CXCL10 levels.
• Human Relevance: Validated the mouse findings in human tissues by showing a significant inverse correlation between Δ133p53α and CXCL10 expression in the human spleen.

4. Results

• Serum Profiling: The Luminex assay confirmed the reduction of IL-6 and identified CXCL10, CXCL1 (KC), and IL-1α as significantly repressed in the serum of Δ133p53α-expressing progeria mice compared to controls.
• Tissue Expression in Progeria Mice:
  • In 15-week-old Lmna^G609G/+^ mice, Cxcl10 mRNA was elevated in the spleen, brain, and liver compared to WT.
  • Transgenic Δ133p53α expression reduced Cxcl10 levels in these organs back to WT levels.
  • This effect persisted in 10-month-old progeria mice.
  • Organ Specificity: No significant changes were observed in the lung, suggesting tissue-specific regulation.
• Natural Aging:
  • In 2-year-old wild-type mice, Cxcl10 expression in the spleen and brain was significantly elevated with age.
  • Transgenic Δ133p53α expression significantly repressed this age-associated increase in the spleen and brain.
• In Vitro Validation:
  • In MEFs, progerin increased Cxcl10, which was reversed within 5 days of Δ133p53α induction.
  • Similarly, Δ133p53α expression in HGPS human fibroblasts significantly reduced CXCL10 mRNA.
• Human Correlation:
  • Analysis of the GTEx dataset revealed a significant inverse correlation between Δ133p53α and CXCL10 expression specifically in the human spleen (an immune-dense organ), supporting the physiological relevance of the findings.

5. Significance

• Therapeutic Potential: The study defines CXCL10 as a key biomarker and therapeutic target for senescence-associated diseases. Since CXCL10 drives inflammation, fibrosis (liver), and neurodegeneration (brain), its repression by Δ133p53α suggests a mechanism for mitigating age-related tissue damage.
• Mechanism of Action: The findings suggest that Δ133p53α exerts anti-aging effects not just by inhibiting senescence entry, but by actively suppressing the SASP inflammatory cascade, specifically targeting the p53-CXCL10 axis.
• Clinical Translation: The results support the development of pharmacological strategies to enhance Δ133p53α activity or use anti-CXCL10 antibodies to treat progeria, inflammatory liver diseases, and neurodegenerative conditions. The inverse correlation in human data strengthens the case for targeting this pathway in human aging.